Neupro is a drug made by the pharmaceutical company UCB Pharma, and was initially developed in 1985 by the University of Groningen, making this the relatively rare medicine that was not developed by a leading global pharmaceutical company. Neupro contains the drug rotigotine, a medicine which is classed as a dopamine agonist which shows affinity for multiple dopamine receptors with D3 being the one it has the highest affinity for. With dopamine being a key neurochemical involved in motivation and pleasure, Neupro also has an anti-depressant effect. Neupro is principally a therapy for treating Parkinson's disease.
By directly agonising dopamine receptors, Neupro is a reliable way to stimulate the body to increase dopamine levels which in turn can enhance physical and cognitive processes for sufferers of Parkinson's disease.
Medically, Neupro is licensed for the treatment of Parkinson's disease, a condition which leads to depleted dopamine levels that cause wide-ranging and debilitating symptoms in patients. Additionally, Neupro is sometimes used to treat restless legs syndrome. Men and women of adult age including early and late stage Parkinson's can take Neupro.
Neupro should be taken as prescribed by a doctor or pharmacist. In general the dose is titrated upwards slowly and being a patchy is usually applied on areas where there is an absence of hair such as shoulder or upper arms. Always refer to product literature.